Argo Biopharma
Shanghai, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
An RNA therapeutics company developing oligonucleotide drugs for cancer.
OncologyRNA Therapeutics
Technology Platform
RNA interference (RNAi) and oligonucleotide platform for silencing cancer-associated genes.
Opportunities
Utilizing RNAi to target oncogenes that are not addressable with conventional small molecules or antibodies.
Risk Factors
Challenges with systemic delivery, stability, and off-target effects of oligonucleotide drugs in oncology.
Competitive Landscape
Competes in the evolving RNAi oncology space against established players and other biotechs.